Free Trial
NASDAQ:APGE

Apogee Therapeutics Q2 2023 Earnings Report

Apogee Therapeutics logo
$39.93 -0.19 (-0.48%)
As of 01:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Apogee Therapeutics EPS Results

Actual EPS
-$3.78
Consensus EPS
-$2.49
Beat/Miss
Missed by -$1.29
One Year Ago EPS
N/A

Apogee Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Apogee Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 28, 2023
Conference Call Time
12:00PM ET

Upcoming Earnings

Apogee Therapeutics' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Apogee Therapeutics Earnings Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Apogee Therapeutics: Engineering Biologic Dominance
Apogee Therapeutics price target lowered to $78 from $80 at BofA
See More Apogee Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email.

About Apogee Therapeutics

Apogee Therapeutics (NASDAQ:APGE), through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

View Apogee Therapeutics Profile

More Earnings Resources from MarketBeat